ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901 and DSMB Approval to Advance Dose Escalation in Phase 1b Retinitis Pigmentosa Trial
08 janv. 2025 08h00 HE
|
ViGeneron GmbH
VG901 is the first-in-class and only clinical-stage therapy designed to deliver the functional CNGA1 gene intravitreally (IVT) to target retinal photoreceptor cells in patients with retinitis...
Retinal Gene Therapy Market Report 2024-2034: Diversification of Targeted Diseases, Combination Therapies, Precision Medicine Approaches, and Gene Editing Driving Opportunities
08 janv. 2025 04h03 HE
|
Research and Markets
Dublin, Jan. 08, 2025 (GLOBE NEWSWIRE) -- The "Retinal Gene Therapy Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering.Overall world revenue for the Retinal Gene...
Braille Institute Library to Host Livestream Event with Pulitzer Prize Finalist Andrew Leland on January 16, 2025
18 déc. 2024 09h00 HE
|
Braille Institute
Braille Institute to host book talk with Pulitzer Prize finalist, Andrew Leland, author of The Country of the Blind: A Memoir at the End of Sight.
EyeDNA Therapeutics Receives Rare Pediatric Disease Designation from FDA for its Investigational Gene Therapy HORA-PDE6b for Patients with Retinal Dystrophy due to PDE6b Gene Mutations
17 déc. 2024 06h00 HE
|
Coave Therapeutics
PDE6b-related Retinitis Pigmentosa is a rare inherited retinal dystrophy affecting up to 3,000 people in the US Symptoms often start in childhood leading to blindness by midlife with no approved...
Latest Published 5 Rare Eye Diseases Market Reports by DelveInsight: Retinitis Pigmentosa, Stargardt Disease, Ocular Melanoma, Uveitis, and Neurotrophic Keratitis
16 déc. 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Latest Published 5 Rare Eye Diseases Market Reports by DelveInsight: Retinitis Pigmentosa, Stargardt Disease, Ocular Melanoma, Uveitis, and...
Verana Health Introduces Qdata Explorer in Advance of 2024 American Academy of Ophthalmology Annual Meeting
09 oct. 2024 09h00 HE
|
Verana Health, Inc.
SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Today, Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD),...
AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B
16 sept. 2024 02h00 HE
|
AAVantgarde Bio
AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study
Retinitis Pigmentosa Clinical Trial Pipeline Insights Featuring 40+ Companies | DelveInsight
07 mai 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, May 07, 2024 (GLOBE NEWSWIRE) -- Retinitis Pigmentosa Clinical Trial Pipeline Insights Featuring 40+ Companies | DelveInsight Retinitis pigmentosa is a genetic disorder characterized...
Retinitis Pigmentosa Market Size Expected to Reach USD 21.40 Bn by 2033
06 mai 2024 09h49 HE
|
Precedence Research
Ottawa, May 06, 2024 (GLOBE NEWSWIRE) -- The global retinitis pigmentosa market size was valued at USD 14.02 billion in 2023 and is predicted to hit around USD 19.90 billion by 2032, a study...
Nacuity Pharmaceuticals Announces Expansion of its Business Advisory Board with Appointment of Rare Disease Advocate Daniel Feller
14 févr. 2024 09h00 HE
|
Nacuity Pharmaceuticals, Inc.
FORT WORTH, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other...